Iron is essential for immature pancreatic beta cells - and deficiency stops them from maturing

Iron deficiency is the most common nutritional deficiency in the world. By most estimates, more than two billion people are affected. The consequences most people know about are fatigue, anemia, and impaired cognitive development. What has been less understood is what iron deficiency does to the pancreas - specifically, to the cells responsible for producing insulin.

A study from Vrije Universiteit Brussel, published in Nature Communications, offers a detailed answer to that question, and it has implications that extend from basic developmental biology into potential new approaches to diabetes prevention and treatment.

Why beta cells are not all equal

Pancreatic beta cells are the body's insulin factories. When blood glucose rises after a meal, beta cells detect the signal and release insulin, which allows cells throughout the body to absorb glucose from the bloodstream. When beta cells fail - whether through autoimmune attack in type 1 diabetes or through dysfunction and depletion in type 2 - the body loses its ability to regulate blood sugar.

What is less commonly appreciated is that beta cells exist in different states of maturity. Immature beta cells, sometimes called progenitor beta cells, must undergo a specific developmental process before they can function properly as insulin producers. This maturation process requires energy, and energy in cells is produced by mitochondria.

The VUB research team found that iron is a necessary ingredient in this process. Young beta cells depend on iron to fuel their mitochondria during the energy-intensive work of maturation. Without adequate iron, the mitochondria cannot function at the level required, and the developmental process stalls.

Mature cells handle the shortage; immature ones cannot

One of the study's key findings is the asymmetry between mature and immature beta cells in their response to iron deficiency. Fully developed, functional beta cells showed significantly greater resilience to temporary iron shortages. They could tolerate reduced iron availability without losing their ability to produce insulin.

Immature beta cells did not share this resilience. Iron deficiency during the developmental window when these cells are trying to mature resulted in a failure to complete that process. The cells did not simply slow down - they lost their developmental trajectory in a way that correlated with iron availability.

This distinction matters for understanding when iron deficiency is most harmful to the pancreas. The relevant window is likely early in development - potentially in utero or in early childhood, when beta cell populations are being established. It may also be relevant during any process that involves generating new beta cells, whether through natural regeneration or laboratory cultivation.

Two paths to clinical relevance

The researchers highlight two practical implications of their findings.

The first concerns metabolic disease prevention. If iron deficiency during critical developmental periods impairs beta cell maturation, populations with high rates of iron deficiency may face elevated risk of inadequate beta cell function, with downstream effects on insulin production and blood glucose regulation. This would add a nutritional dimension to the risk factors for type 2 diabetes that extends beyond diet composition and physical activity.

The second implication concerns laboratory cultivation of beta cells for diabetes treatment. One of the active areas of research in diabetes therapy involves growing functional beta cells outside the body - either from stem cells or from donor cells - and transplanting them into patients who have lost beta cell function. A persistent challenge in this work is getting laboratory-grown beta cells to mature fully and function like native cells do.

The VUB study suggests that iron availability during the cultivation process may be a variable that has been underappreciated. If immature beta cells cannot mature without adequate iron, then optimizing iron in the culture environment could improve the yield and functionality of laboratory-grown cells.

What the study does not yet resolve

The research was conducted in cell and animal models, which means the direct translation to human clinical outcomes requires further investigation. The mechanistic picture is coherent - iron supports mitochondrial function, mitochondria support the energy demands of maturation, maturation is required for function - but confirming that iron deficiency in humans produces the specific beta cell deficits observed in the models would require prospective studies in human populations.

It also remains unclear whether the effects are fully reversible. If iron deficiency during a critical developmental window leaves a lasting deficit in beta cell populations, correcting the deficiency later may not restore the cells that failed to mature. If the effects are reversible within a certain time window, early detection and correction of iron deficiency would be more valuable than later intervention.

These are answerable questions. What the VUB study provides is the mechanistic foundation that makes them worth asking urgently.